Want to see QGEN full AI Analyst Report?
QGEN Stock Chart & Stats
$41.24
$0.22(0.49%)
At close: 4:00 PM EST
$41.24
$0.22(0.49%)
Day’s Range― - ―
52-Week Range$32.53 - $57.82
Previous CloseN/A
Volume260.87K
Average Volume (3M)2.37M
Market Cap
$8.65B
Enterprise Value$8.54B
Total Cash (Recent Filing)$646.29M
Total Debt (Recent Filing)$1.65B
Price to Earnings (P/E)22.0
Beta0.58
Next Earnings
Jul 23, 2026EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend Yield3.31%
Share Statistics
EPS (TTM)1.89
Shares Outstanding206,074,750
10 Day Avg. Volume2,528,201
30 Day Avg. Volume2,370,610
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.61
Price to Sales (P/S)4.71
P/FCF Ratio21.72
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue4.07
Enterprise Value/Gross Profit6.61
Enterprise Value/Ebitda10.98
Forecast
1Y Price Target
$41.18Price Target Upside-0.15% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)2.42
Revenue Forecast (FY)$2.15B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Installed BaseQiagen's core business is built on high-frequency consumables and instruments that create durable pull-through demand. Installed platforms drive repeat kit/reagent purchases, supporting predictable recurring revenue, steady margins and long-term customer stickiness across research and clinical workflows.
Strong TTM Revenue Acceleration And MarginsA substantial TTM revenue acceleration alongside high gross and healthy net margins signals robust demand and operational leverage. Sustained top-line momentum plus margin levels indicate differentiated products and pricing power that can support earnings resilience over the next several quarters.
Manageable Leverage And Improving ROELower leverage relative to prior years and an improved ROE enhance financial flexibility. A reasonable debt load reduces refinancing risk and supports targeted capital allocation (R&D, tuck-ins, dividends) while improved return on equity reflects better capital efficiency and profitability.
Bears Say
Weak Free Cash Flow ConversionFree cash flow weakness and sub‑optimal conversion (FCF ~69% of net income) reduce the company's ability to self-fund investments, dividends or M&A without tapping capital markets. Choppy FCF also limits resilience to demand shocks and complicates multi‑quarter planning.
QuantiFERON Concentration & Demand RiskMaterial exposure to QuantiFERON and immigration testing volumes creates product concentration risk. Policy or regional testing shifts can drive abrupt revenue swings, as seen in Q1, pressuring growth guidance and forcing reliance on other pillars to offset structural declines.
Profitability And Margin VolatilityHistoric swings from a 4% net margin trough to stronger recent margins highlight operational sensitivity to product mix, discontinued lines and macro headwinds. Persistent margin volatility undermines earnings predictability and complicates long‑term capital allocation and investor visibility.
Qiagen News
QGEN FAQ
What was Qiagen’s price range in the past 12 months?
Qiagen lowest stock price was $32.53 and its highest was $57.81 in the past 12 months.
What is Qiagen’s market cap?
Qiagen’s market cap is $8.65B.
When is Qiagen’s upcoming earnings report date?
Qiagen’s upcoming earnings report date is Jul 23, 2026 which is in 12 days.
How were Qiagen’s earnings last quarter?
Qiagen released its earnings results on May 06, 2026. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.542 by -$0.002.
Is Qiagen overvalued?
According to Wall Street analysts Qiagen’s price is currently Overvalued.
Does Qiagen pay dividends?
Qiagen pays a Semiannually dividend of $0.35 which represents an annual dividend yield of 3.31%. See more information on Qiagen dividends here
What is Qiagen’s EPS estimate?
Qiagen’s EPS estimate is 0.6.
How many shares outstanding does Qiagen have?
Qiagen has 206,074,750 shares outstanding.
What happened to Qiagen’s price movement after its last earnings report?
Qiagen reported an EPS of $0.54 in its last earnings report, missing expectations of $0.542. Following the earnings report the stock price went down -2.701%.
Which hedge fund is a major shareholder of Qiagen?
Currently, no hedge funds are holding shares in QGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qiagen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.18 (-0.15% Downside)
$41.18 (-0.15% Downside)
Blogger Sentiment
Bullish
QGEN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.80%
12-Months-Change
Fundamentals
Return on Equity
11.28%
Trailing 12-Months
Asset Growth
4.27%
Trailing 12-Months
Company Description
Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
QGEN Stock 12 Month Forecast
Average Price Target
$41.18
▼(-0.15% Downside)
Technical Analysis
Ownership Overview
0.62% Insiders
25.42% Mutual Funds
0.06% Other Institutional Investors
55.23% Public Companies and
Individual Investors